Home

Halozyme Therapeutics, Inc. - Common Stock (HALO)

57.63
+0.86 (1.51%)

Halozyme Therapeutics is a biotechnology company that focuses on the development and commercialization of novel therapeutics for the treatment of various diseases, particularly in oncology and chronic diseases

The company specializes in its proprietary proprietary enzyme technology, which enhances the delivery and effectiveness of therapeutics, including biologics and monoclonal antibodies. Halozyme collaborates with other pharmaceutical companies to improve their drug formulations and patient delivery systems, ultimately aiming to provide innovative solutions that enhance treatment outcomes for patients.

SummaryNewsPress ReleasesChartHistoricalFAQ
Kaskela Law LLC Announces Shareholder Investigation of Halozyme Therapeutics, Inc. (HALO) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Halozyme Therapeutics, Inc. (“Halozyme”) (NASDAQHALO) on behalf of the company’s shareholders.
By Kaskela Law LLC · Via Business Wire · September 17, 2024
ViiV Healthcare and Halozyme enter global collaboration and license agreement for ENHANZE® drug delivery technology to enable development of “ultra long-acting” medicines for HIV
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives exclusive access to Halozyme’s ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for specific targets used in the treatment and prevention of HIV.
By ViiV Healthcare · Via Business Wire · June 22, 2021